Merrill maintains Amylin at sell

Amylin Pharmaceuticals Inc. was maintained at sell by Merrill Lynch after the company reported a third-quarter loss of $0.65 per share, wider than Merrill's estimate of $0.57 and consensus of $0.58. Analyst Thomas McGahren said the difference was due to lower-than-expected Byetta sales and higher sales and marketing expenses. Merrill increased its loss per share for 2005 to $1.95 from $1.85 due to higher expected selling, general and administration expenses and lower collaborative revenue. Shares of the San Diego-based pharmaceutical company were down $4.12, or 10.84%, at $33.87 on volume of 11,502,346 shares versus the three-month running average of 3,684,750 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.